Pasithea Therapeutics (KTTA) vs Rocket One (RKTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Rocket One (RKTO) over the past year, losing 40.8% versus a loss of 61.1%. Over five years, RKTO leads with a -97.8% price change compared with -99.2% for KTTA. Rocket One is the larger company by market cap ($16.2 million vs $15.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | RKTO |
|---|---|---|
| Share price | $0.4675 | $0.6493 |
| Market cap | $15.62M | $16.17M |
| 1-day change | +6.03% | +0.50% |
| YTD return | -63.76% | -34.41% |
| 1-year return | -40.82% | -61.12% |
| 5-year return | -99.22% | -97.76% |
| EPS (TTM) | $-1.59 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.06 | $2.45 |
| 52-week low | $0.281 | $0.489 |
| Distance from 52-week high | -77.31% | -73.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +541.71% | — |
| Average volume | 226.32K | 554.01K |
| Shares outstanding | 33.41M | 24.90M |
| Employees | 5 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed RKTO by 20.3 percentage points over the past year.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
KTTA vs RKTO FAQ
Which is bigger, Pasithea Therapeutics or Rocket One?
Rocket One (RKTO) is larger, with a market capitalization of $16.17M compared with $15.62M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, KTTA or RKTO?
KTTA returned -40.82% over the past 12 months, compared with -61.12% for RKTO (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and Rocket One in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.